12:00 AM
 | 
May 20, 2013
 |  BC Week In Review  |  Company News  |  Other News

Neumedicines, U.S. Department of Health and Human Services (HHS) other news

Neumedicines said HHS's Biomedical Advanced Research and Development Authority (BARDA) notified the company that BARDA intends to exercise its option for the continued development of HemaMax to treat hematopoietic syndrome of acute radiation sickness. The company said the goal of the option is to conduct animal studies to compare and...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >